New formulation of daratumumab to be tested

Halozyme Therapeutics, the American biotechnology company collaborating with Janssen Biotech., Inc. to develop new formulations for drugs, has announced plans for a Phase I trial of a subcutaneous formulation of daratumumab in myeloma patients. Daratumumab is a monoclonal anti-CD38 antibody that is showing promise as a potential treatment for myeloma. It is currently administered by…

Details